Cystic Fibrosis Foundation Development Award	6 Months Ended
Jun. 30, 2022
Research and Development [Abstract]
Cystic Fibrosis Foundation Development Award	12. Cystic Fibrosis Foundation Development Award In October 2020, the Company was awarded $2.4 million from the Cystic Fibrosis Foundation, or CFF, to support the clinical development of CB-280 in cystic fibrosis. The award would be paid in installments upon the achievement of certain milestones. The Company recognized the CFF milestones awards as a reduction to research and development expenses in the accompanying unaudited consolidated statements of operations in the period the milestones were achieved and expenses incurred. For the three and six months ended June 30, 2022 and 2021, no amounts from the CFF were recognized as a reduction of research and development expenses. In May 2022, the Company made the decision to no longer pursue further development of CB-280 in cystic fibrosis at this time, and as a result, in June 2022, CFF terminated the award agreement.

Cystic Fibrosis Foundation Development Award

6 Months Ended

Jun. 30, 2022

Cystic Fibrosis Foundation Development Award

12. Cystic Fibrosis Foundation Development Award

In October 2020, the Company was awarded $2.4 million from the Cystic Fibrosis Foundation, or CFF, to support the clinical development of CB-280 in cystic fibrosis. The award would be paid in installments upon the achievement of certain milestones. The Company recognized the CFF milestones awards as a reduction to research and development expenses in the accompanying unaudited consolidated statements of operations in the period the milestones were achieved and expenses incurred. For the three and six months ended June 30, 2022 and 2021, no amounts from the CFF were recognized as a reduction of research and development expenses.

In May 2022, the Company made the decision to no longer pursue further development of CB-280 in cystic fibrosis at this time, and as a result, in June 2022, CFF terminated the award agreement.